Imaplix

Apremilast, the active ingredient in Imaplix, is a phosphodiesterase 4 (PDE4) inhibitor presented as a tablet for oral use. It treats psoriasis and psoriatic arthritis in adult patients. GNH USA supplies Imaplix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imaplix is a phosphodiesterase 4 inhibitor used in chronic inflammatory skin and joint disorders.

Psoriasis: reduces skin lesions, scaling and erythema. Psoriatic arthritis: alleviates joint pain, swelling and improves functional ability.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, often transient. - Headache: mild to moderate intensity. - Upper respiratory tract infection: nasopharyngitis symptoms. - Weight loss: gradual reduction in body weight. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Depression: new or worsening mood changes. - Suicidal ideation: thoughts of self‑harm requiring immediate evaluation. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Pancreatitis: abdominal pain with elevated enzymes. - Hepatic injury: abnormal liver function tests. - Severe infections: opportunistic infections in immunocompromised patients.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown; weigh potential infant exposure. - Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver enzymes regularly. - Concomitant immunosuppressants: use with caution due to infection risk. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Apremilast may interact with several drug classes; assess concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase apremilast exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Monoamine oxidase inhibitors: risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect. - Oral contraceptives: possible reduced efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased gastrointestinal irritation. - Methotrexate: enhanced hepatotoxicity risk. - Antidepressants (SSRIs): monitor for mood changes.